Home › Trials › NCT06810505

Using Atogepant tablets to prevent migraines in teens aged 12 to 17

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age

Phase 3 Interventional AbbVie · NCT06810505

This study is testing if Atogepant tablets can help prevent migraines in teenagers aged 12 to 17.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment420 (estimated)
Ages12 Years to 17 Years
SexAll
SponsorAbbVie Industry-sponsored
Locations61 sites (Huntsville, Alabama and 60 other locations)
Trial IDNCT06810505 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness and safety of Atogepant, an oral medication, in preventing chronic migraines in adolescents aged 12 to 17 years. Participants will be randomly assigned to receive either Atogepant or a placebo, with neither the participants nor the researchers knowing which treatment is being administered (double-blind). The study aims to assess adverse events and changes in disease activity over the treatment period. It is designed to provide insights into how well Atogepant can reduce the frequency of migraine attacks in this age group.

Who should consider this trial

Good fit: Ideal candidates are adolescents aged 12 to 17 with a history of chronic migraines for at least 6 months.

Not a fit: Patients with significant hypertension or other serious health conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the frequency and severity of migraines in adolescents, improving their quality of life.

How similar studies have performed: Previous studies have shown positive results with Atogepant in adult populations, suggesting potential for success in younger patients.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* History of chronic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) (2018) for at least 6 months as of Visit 1.
* During the last 28 days of the screening/baseline period, and as per eDiary:

  * Participant must have completed the eDiary for a minimum of 20 out of 28 days.
  * Participant has \>= 15 headache days.
  * Participant has \>= 8 migraine days.

Exclusion Criteria:

* Clinically significant hypertension per investigator's judgment.
* History of any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular or neurologic disease.

Where this trial is running

Huntsville, Alabama and 60 other locations

+11 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Chronic MigraineMigraineAtogepantQULIPTAAQUIPTA
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.